Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPIV Phase 1 in Healthy Flavivirus-Naïve and Primed Adults
NCT02963909Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZPIV in Zika virus infection (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of Serious Adverse Events, Occurrence of Solicited Local Adverse Events and 2 more. Started Nov 2016; status: completed.
02
Drugs
ZPIV
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT02963909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963909.